If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and 3.5% in the last month. This comes after a year where the stock dipped 3.8%, not to mention a 12.5% decline over the last three years. While these moves may seem discouraging on the surface, they also open up new questions around opportunity and risk, especially with major headlines swirling around tariffs and regulatory uncertainty.

Pharma stocks like Roche are being influenced by policy developments, including the U.S. administration’s looming decision on pharmaceutical tariffs and ongoing discussions between Swiss leaders and Roche management about the international trade environment. At the same time, the news that Roche is set to resume shipments for Sarepta’s Elevidys outside the U.S. hints at growing momentum in the company’s global operations. These dynamics, combined with the stock’s relatively modest five-year loss of 5.9%, may point to shifting investor sentiment and a possible inflection point for the business.

But here is where things get interesting: when evaluated across six key valuation checks, Roche scores a 4. This means it is undervalued in four out of six important criteria. That is a solid start for anyone seeking value. Still, there is more to the story than just these numbers. Next, we will unpack each valuation approach so you can see where Roche stands, before discussing an even sharper way to truly gauge the company’s real worth.

Why Roche Holding is lagging behind its peers

The Discounted Cash Flow (DCF) model is a widely used approach to estimate a company's intrinsic value. It does this by projecting the company’s future free cash flows and then discounting them back to today’s value, providing a look at what the business is truly worth based on its expected financial performance.

For Roche Holding, current Free Cash Flow (FCF) sits at CHF 14.08 billion. Analysts estimate FCF will climb steadily over the next five years, with Simply Wall St’s model projecting Roche’s FCF reaching CHF 20.54 billion by 2029. Beyond analyst projections, further growth calculations are based on moderate sector assumptions, which pushes the ten-year outlook even higher.

Based on these cash flows, the DCF calculation gives an intrinsic fair value of CHF 776.48 per share, compared to the recent share price of CHF 253.50. This suggests the stock is trading at a 67.4% discount to its calculated fair value.

In summary, while market sentiment is cautious, Roche’s underlying cash flow strength according to the DCF model points to significant undervaluation.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Roche Holding.

Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 67.4%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is widely regarded as one of the most useful ways to value profitable companies like Roche Holding. It provides a snapshot of how much investors are willing to pay for each Swiss franc of earnings, making it especially relevant for established businesses with stable profits. Growth potential and risk levels play a major role in what is considered a "normal" or "fair" PE ratio. Companies expected to grow quickly or with lower risks generally command higher PE multiples, while those facing headwinds will often trade at a discount.

Roche’s current PE ratio stands at 22.9x. Compared to the Pharmaceuticals industry average of 24.3x and a peer group average of 68.4x, Roche is trading below both these benchmarks. On the surface, this suggests a conservative valuation relative to both competitors and the broader sector.

However, rather than relying solely on industry averages, the Simply Wall St proprietary “Fair Ratio” offers an advanced benchmark by analysing factors such as Roche’s expected earnings growth, risks, profit margins, market capitalization, and industry conditions. For Roche, this “Fair Ratio” is calculated at 36.6x. Since this is well above the company’s current PE, the data indicates that the stock could be undervalued based on its fundamentals, not just its relative positioning.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives. A Narrative is simply your story or perspective on a company, which brings together your assumptions about its future revenues, earnings, and margins into a financial forecast and, ultimately, a fair value.

Instead of focusing only on fixed numbers, Narratives help you see how your investment thesis connects to real-world outcomes. On Simply Wall St’s Community page, used by millions of investors, you can easily pick or create a Narrative for Roche Holding. This approach lets you compare the Fair Value you believe in with the live market Price, guiding your buying or selling decisions in a way that actually fits your view of the business.

The best part is that Narratives update automatically whenever new information becomes available, such as a news release or earnings update, keeping your analysis relevant and dynamic. For example, some Roche Narratives expect a fair value of CHF 438.0 per share based on strong growth in diagnostics and pipeline advances. Others are more cautious, suggesting CHF 230.0 given competitive and regulatory pressures.

This powerful, user-friendly tool enables you to invest based on your convictions, informed by both numbers and the bigger story.

Do you think there's more to the story for Roche Holding? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ROG.swx.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com